conference

exhibit

Madrigal Pharmaceuticals Inc

data

$CACO Perhaps the biggest kick in the nuts is seeing this garbage $MDGL hit all time highs yesterday at $315 after reporting NASH data.

$MDGL as good as the phase 3 data was this is fuckin nuts and the manipulation couldn&#39;t be more blatant.

Data is not even as good as some competitors

$MDGL So many irregularities with the data.

$MDGL if you look at the data closer, it is actually a disgused failure.

This market is a shit show that wants to collapse and any bad data this will get eviscerated!

The data is dropping with an 830am eastern time conference call.

Leaving data to last possible minute isn’t a good sign.

market

$MDGL this stock market is so full of shit.

$MDGL $VKTX markets going up and this aint.

Suddenly you realize the market is not as big as they are claiming!

$MDGL This is a perfect example of what is wrong with this market still.

show

$MDGL Today is going to be an absolute shit show likely with markets tanking and no news here.

strike

suck

$MDGL For all the mean and rude assholes out there.

WTF Jerry even the neighborhood asshole can be civil.

$MDGL down down down let’s go bears fuck this piece of crap

$MDGL a lot of options for tomorrow are being fucked with.

$TGTX saw this activity Friday afternoon on $MDGL Dec 16th and the next Monday it went up over 200% and it had a conference call that morning at 8:30AM EST as well 🍻

However, MDGL will be the darling of JP Morgan conference.

They might garner a lot of interest in JPM conference.

Not only do we get data, we get a conference call. Bullish!

This will go beyond parabolic on good data … literally no shares out there unless they offer new ones … $MDGL $VKTX $SLS $SAVA

I don’t have to wait for fda approval for such low MC like ETNB is good promising data in next 3 weeks .. it can 3x my investments .. like AKRO is seating at 2B… ETNB HAS a strong potential for 2-3x from here next 3-4 weeks

This is an outstanding setup for $VKTX&#39;s VK2809 P2b study which is scheduled to release data in Q2 2023.

Well for genius shorts who can&#39;t read medical data, this is a GREAT shorting opportunity.

$VKTX from what I&#39;ve read from the preliminary trial data, the molecule is good, maybe better than $MDGL and has applications in weightloss.

$MDGL $ALT $TERN will wind up better with much better data.

With slam-dunk efficacy data and two years worth of safety data with no significant adverse safety events reported, Resmetirom has a clear path forward to accelerated approval.

$MDGL their PhIII data are so resoundingly positive that this has been termed a “watershed moment” and a “shock win” for the company.

bull

$MDGL cheers bulls great finish to the year!

$MDGL congrats to all longs and bulls here.

$MDGL benefits of owning low float market king bull.

$MDGL  
The MM now  
ok guys we did a great job this week let&#39;s celebrate Christmas and enjoy the fool&#39;s bulls&#39; money

$MDGL The horns on this bull are massive.

$MDGL - Congrats bulls on MDGL&#39;s stellar P3 performance and strong price run especially leading up to the holidays.

trial

$MDGL this is the cream of the crop, we already have stellar phase 3 results in the books.

$MDGL nice opportunity to add a few hundred shares here 😆  the celebration of shorts today reminded me when the stock price dropped sharply by 27% in a couple of days before trial readout.

Based on my multi year knowledge in NASH field, mdgl management so far did the best execution of clinical development - too many things to exemplify here!

Study results showed statistically significant absolute reductions in hepatic fat fraction at week 13 with pegozafermin administered every week or every two weeks compared to placebo.

After reaching its endpoints on its Phase 3 data we have seen a $240 spike!

Plus, remember this company is light years ahead of its competitors none of whom have had success with Phase 3. Bullish!

$VKTX Truth: VKTX increased more than 100% last 3 days since $MDGL has Phase 3 results.

Top Stocks matching your search for "conference exhibit"

Click Learn More to know about Stock Advisor's top picks. We've 3x'd the S&P 500 over the last 20 years.

MDGL

Madrigal Pharmaceuticals Inc

-10.68%

$275.00 - $245.64

Jan, 10, 2023

Dec, 28, 2022

MDGL

Madrigal Pharmaceuticals Inc

-10.68%

$275.00 - $245.64

Jan, 10, 2023

Dec, 28, 2022

Dec, 22, 2022

Dec, 20, 2022

Dec, 18, 2022